Anavex Life Sciences Corp (AVXL)

[boi568]

You conclude, "I do not think there will be much share price appreciation if CMA is the outcome."

So I asked ChatGTP,

"Can you find examples, or better yet stats, on the number of EMA CMA approvals that subsequently led to a drug conditionally approved being pulled off the EU market?"

The heart of its answer was "Short answer: revocations are **very rare**. Examples exist [ . . . ] and using public EMA / literature counts you get **only a small handful** of CMAs subsequently pulled from the EU market — roughly **3 of ~89 CMAs** as of end-2023 (˜**3.4%**)."

Further, even a CMA would boost the odds of an FDA approval, whether through the CNPV or otherwise. I think you are being overly pessimistic regarding how the share price would react to a conditional approval.